Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
North American Coral Snake Antivenin (Equine)
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
North American Coral Snake Antivenin (Equine) is a horse-derived immunoglobulin G (IgG) antibody preparation indicated for the treatment of envenomation caused by bites from North American coral snakes, specifically Micrurus fulvius fulvius (Eastern Coral Snake) and Micrurus fulvius tenere (Texas Coral Snake). The antivenom is produced by immunizing healthy horses with coral snake venom and then fractionating their blood to obtain serum globulins. It is supplied as a sterile lyophilized powder for intravenous administration after reconstitution. The mechanism of action involves specific binding and neutralization of coral snake venom toxins, thereby preventing or reversing neurotoxic effects such as lower motor neuron paralysis. This product has been shown to decrease intubation rates and ventilator time in patients with confirmed envenomation[1][2][5][6].
- Brand names
- North American Coral Snake AntiveninNACSA
- Other names
- Antivenin (Micrurus fulvius) (Equine Origin)North American Micrurus immune F(ab')2 equine
02
Targets
MfVT (Micrurus fulvius venom toxin proteins)
Beyond the preview
Go deeper on North American Coral Snake Antivenin (Equine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on North American Coral Snake Antivenin (Equine).